Malignant lymphoma, large cell, diffuse.
恶性淋巴瘤，大细胞，弥漫性。
Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
The pathologic diagnosis was diffuse small cleaved cell lymphoma.
病理诊断为弥漫小核裂细胞型。
Conclusions the treatment effectiveness in newly diagnosed diffuse large-B-cell lymphoma in the elderly has been improved by an individual treatment plan according to evidence-based methods.
结论采用循证医学的方法为初治的老年弥漫性大B细胞淋巴瘤患者制定化疗方案可有效提高治疗效果。
Histologicallly, all cases were diffuse non - Hodgkin lymphoma. 9 cases were B and 1 case were t immunophenotype.
组织学形态均为恶性弥漫性非霍奇金淋巴瘤，免疫表型B细胞来源9例，T细胞来源1例。
Occasionally, CD5 antigen is also expressed on a subset of B cells. Mantle cell lymphomas (same as diffuse centrocytic lymphomas) are CD5+ while the follicle center cell lymphoma are CD5-.
外套层细胞淋巴瘤常常为CD5阳性表达，而滤泡中心性淋巴瘤常为阴性。
Conclusions Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
结论弥漫性大B细胞性淋巴瘤治疗后生存期可通过肿瘤微环境中的免疫细胞、纤维化、血管形成的差异而影响。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
应用推荐